dc.rights.license | Reconocimiento 4.0 Internacional |
dc.contributor.advisor | Rondón Herrera, Federico |
dc.contributor.advisor | Patricia Rojas, Angela |
dc.contributor.author | Delgado Marrugo, Raul David |
dc.coverage.temporal | 2016-2022 |
dc.date.accessioned | 2024-09-05T18:33:09Z |
dc.date.available | 2024-09-05T18:33:09Z |
dc.date.issued | 2024 |
dc.identifier.uri | https://repositorio.unal.edu.co/handle/unal/86796 |
dc.description | ilustraciones, diagramas, tablas |
dc.description.abstract | Introducción: En pacientes con miopatías inflamatorias idiopáticas (MII) se han correlacionado autoanticuerpos y alelos HLA con fenotipos clínicos en diferentes regiones del mundo.
Objetivo: Evaluamos las características inmunogénicas en una población de la ciudad de Bogotá, Colombia.
Métodos: Estudio transversal de 68 pacientes con MII. Panel de 15 autoanticuerpos específicos y asociados a miositis. Se realizó determinación de alelos HLA-DQA1, DQB1, DR mediante técnica de reacción en cadena de la polimerasa en tiempo real.
Resultados: La población del estudio tenía una edad media de 52,2 años, y el 73% de los participantes eran mujeres. En el grupo, los tipos de MII más frecuentemente observados fueron Dermatomiositis (DM) (58%), Polimiositis (PM) (25%), Síndrome Antisintetasa (ASyS) (5,8%), Miositis Necrotizante Inmunomediada (MNIM) (5,8%) y Miositis por Cuerpos de Inclusión (MCI) (4%). Se realizó un panel de autoanticuerpos en 23 pacientes. Los resultados mostraron que Mi-2 (52%) era el anticuerpo más prevalente relacionado con DM (83%), características clínicas Gottron (75%) y Heliotropo (58%) con HLA-DQB1*03 (50%); ASyS Jo-1 (7; 30%) relacionados con PM (85%), neumonía intersticial inespecífica (NINE) (14%) y HLA-DQB1*03 (28%); anticuerpos asociados a Ku (13%) relacionados con DM (66%), Gottron y Heliotropo (66%), NINE (33%) y HLA-DQB1*03 (33%)
Conclusiones: Este es el primer estudio realizado en Colombia que determina alelos HLA y autoanticuerpos de miositis en pacientes con MII, se encontraron diferentes co-prevalencias entre las manifestaciones clínicas y el perfil inmunogénico, lo que permite conocer las características de la población en nuestra comunidad e incentiva la investigación para estudios con una población mayor (Texto tomado de la fuente). |
dc.description.abstract | Introduction: In patients with idiopathic inflammatory myopathies (IIM) autoantibodies and HLA alleles have been correlated with clinical phenotypes in different regions worldwide.
Aim: We evaluated immunogenic characteristics in a population from the city of Bogota, Colombia.
Methods: A cross-sectional study of 68 patients with IIM. Panel of 15 specific and myositisassociated autoantibodies, determination of HLA-DQA1, DQB1, DR alleles was performed by real-time polymerase chain reaction technique.
Results: The study population had a mean age of 52.2 years, with 73% of the participants being female. Among the group, the most frequently observed types of IIM were Dermatomyositis (DM) (58%), Polymyositis (PM) (25%), Antisynthetase Syndrome (ASyS) (5.8%), Immune-Mediated Necrotizing Myositis (IMNM) (5.8%), and Inclusion Body Myositis (IBM) (4%). Table 1 shows other clinical features. An autoantibody panel was performed on 23 patients. Results showed that Mi-2 (52%) was the most prevalent antibody, relating to DM (83%), clinical features Gottron′s (75%) and Heliotrope (58%) with HLA-DQB1*03 (50%); ASyS Jo-1 (7; 30%) related to PM (85%), Nonspecific interstitial
pneumonia (NSIP) (14%) and HLA-DQB1*03 (28%); Ku-associated antibodies (13%) related to DM (66%), Gottron and Heliotrope (66%), NSIP (33%) and HLA-DQB1*03 (33%).
Conclusions: This is the first study conducted in Colombia determining HLA alleles and myositis autoantibodies in patients with MI, different co-prevalences were found between clinical manifestations and immunogenic profile, which allows us to know the characteristics of the population in our community and encourages research for studies with a larger population. |
dc.format.extent | 73 páginas |
dc.format.mimetype | application/pdf |
dc.language.iso | spa |
dc.publisher | Universidad Nacional de Colombia |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.subject.ddc | 610 - Medicina y salud::616 - Enfermedades |
dc.subject.ddc | 610 - Medicina y salud::615 - Farmacología y terapéutica |
dc.title | Prevalencia y coprevalencia de los factores inmuno genéticos en pacientes con miopatías inflamatorias idiopáticas de un centro de tercer nivel de complejidad |
dc.type | Trabajo de grado - Especialidad Médica |
dc.type.driver | info:eu-repo/semantics/doctoralThesis |
dc.type.version | info:eu-repo/semantics/acceptedVersion |
dc.publisher.program | Bogotá - Medicina - Especialidad en Medicina Interna |
dc.contributor.researchgroup | Biología Celular y Autoinmunidad |
dc.coverage.city | Bogotá |
dc.coverage.country | Colombia |
dc.description.degreelevel | Especialidades Médicas |
dc.description.degreename | Especialista en Medicina Interna |
dc.description.methods | Estudio observacional corte transversal descriptivo. Pacientes >18 años con diagnóstico de miopatía inflamatoria probable o definitiva
dado por los criterios EULAR/ACR 2017 en pacientes hospitalizados o que
asistieron a consulta externa de reumatología en el Hospital Universitario Nacional,
durante el periodo entre enero de 2016 a julio de 2022. Pacientes con miopatías inflamatorias probables o definitivas secundarias a
procesos neoplásicos. |
dc.identifier.instname | Universidad Nacional de Colombia |
dc.identifier.reponame | Repositorio Institucional Universidad Nacional de Colombia |
dc.identifier.repourl | https://repositorio.unal.edu.co/ |
dc.publisher.faculty | Facultad de Medicina |
dc.publisher.place | Bogotá, Colombia |
dc.publisher.branch | Universidad Nacional de Colombia - Sede Bogotá |
dc.relation.references | Damoiseaux J, Vulsteke JB, Tseng CW, Platteel ACM, Piette Y, Shovman O, et al. Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmun Rev. 2019 Mar 1;18(3):293–305. |
dc.relation.references | Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies-a guide to subtypes, diagnostic approach and treatment. Clinical Medicine. 2017;17(4):322– 30. |
dc.relation.references | Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: An administrative claims analysis. BMC Musculoskelet Disord. 2012;13. |
dc.relation.references | McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018 May 1;14(5):290–302. |
dc.relation.references | Pina Cruellas MG, Trindade Viana V dos S, Levy-Neto M, Carlos de Souza FH, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics. 2013 Jul;68(7):909–14. |
dc.relation.references | O’Hanlon TP, Carrick DM, Arnett FC, Reveille JD, Carrington M, Gao X, et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs
define clinicopathologic groups in Caucasians. Medicine. 2005 Nov;84(6):338–49. |
dc.relation.references | Miller FW, Chen W, O’Hanlon TP, Cooper RG, Vencovsky J, Rider LG, et al. Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. Genes Immun. 2015 Oct
1;16(7):470–80. |
dc.relation.references | Patricia K, Castro V. Descripción de los anticuerpos, y manifestaciones clínicas de pacientes con polimiositis y dermatomiositis. 2014. |
dc.relation.references | Rothwell S, Cooper RG, Lundberg IE, Miller FW, Gregersen PK, Bowes J, et al. Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Ann Rheum Dis. 2016 Aug 1;75(8):1558–66. |
dc.relation.references | Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol [Internet]. 2016;30(1):149–68. Available from: https://www.sciencedirect.com/science/article/pii/S1521694216300225 |
dc.relation.references | Mammen AL. Autoimmune Myopathies. Continuum (N Y) [Internet]. 2016;22(6):1852–70. Available from: www.ContinuumJournal.com |
dc.relation.references | McGrath ER, Doughty CT, Amato AA. Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics [Internet]. 2018 Oct 14;15(4):976–94. Available from: https://doi.org/10.1007/s13311-018-00676-2 |
dc.relation.references | Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies.Presse Med [Internet]. 2011;40(4, Part 2):e237–47. Available from: https://www.sciencedirect.com/science/article/pii/S0755498211000534 |
dc.relation.references | Hilton-Jones D. Inflammatory muscle diseases. Curr Opin Neurol [Internet].
2001;14(5). Available from: https://journals.lww.com/coneurology/fulltext/2001/10000/inflammatory_muscle_diseases.7.aspx |
dc.relation.references | Dimachkie MM, Barohn RJ, Amato AA. Idiopathic inflammatory myopathies. Vol.32, Neurologic Clinics. W.B. Saunders; 2014. p. 595–628. |
dc.relation.references | Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. The Lancet [Internet]. 2001 Jan 13;357(9250):96–100. Available from: https://doi.org/10.1016/S0140-6736(00)03540-6 |
dc.relation.references | Clark KEN, Isenberg DA. A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol [Internet]. 2018 Jan 1;25(1):13–23. Available from: https://doi.org/10.1111/ene.13357 |
dc.relation.references | Stenzel W, Goebel HH, Aronica E. Review: Immune-mediated necrotizing myopathies – a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol [Internet]. 2012 Dec 1;38(7):632–46.
Available from: https://doi.org/10.1111/j.1365-2990.2012.01302.x |
dc.relation.references | Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve [Internet]. 2010 Feb 1;41(2):185–90. Available from:
https://doi.org/10.1002/mus.21486 |
dc.relation.references | Noguchi E, Uruha A, Suzuki S, Hamanaka K, Ohnuki Y, Tsugawa J, et al. Skeletal Muscle Involvement in Antisynthetase Syndrome. JAMA Neurol [Internet]. 2017 Aug 1;74(8):992–9. Available from: https://doi.org/10.1001/jamaneurol.2017.0934 |
dc.relation.references | Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol [Internet]. 2010;10(3):346–52. Available from: https://www.sciencedirect.com/science/article/pii/S1471489210000275 |
dc.relation.references | Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn [Internet]. 2010 May 1;4(3):241–50. Available from: https://doi.org/10.1517/17530051003713499 |
dc.relation.references | Frikha F, Saidi N, Snoussi M, Ben Salah R, Ben Ayed M, Daoud E, et al. Le syndrome des antisynthétases : à propos de quatre observations et revue de la littérature. Rev Pneumol Clin [Internet]. 2012;68(6):351–60. Available from:
https://www.sciencedirect.com/science/article/pii/S0761841712000971 |
dc.relation.references | Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol [Internet]. 2016;29(5). Available from: https://journals.lww.com/coneurology/fulltext/2016/10000/advances_in_serological_diagnostics_of.18.aspx |
dc.relation.references | Bevilacqua JA, Earle N. Inflammatory myopathies. Vol. 29, Revista Medica Clinica Las Condes. Ediciones Doyma, S.L.; 2018. p. 611–21. |
dc.relation.references | Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M de, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017 Dec 1;76(12):1955–64. |
dc.relation.references | Nakashima R. Clinical significance of myositis-specific autoantibodies. Immunol Med [Internet]. 2018 Jul 3;41(3):103–12. Available from: https://doi.org/10.1080/25785826.2018.1531188 |
dc.relation.references | Zampeli E, Venetsanopoulou A, Argyropoulou OD, Mavragani CP, Tektonidou MG, Vlachoyiannopoulos PG, et al. Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clin Rheumatol [Internet]. 2019;38(1):125–32. Available from: https://doi.org/10.1007/s10067-018-4267-z |
dc.relation.references | Temmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T, et al. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis. Medicine (United States). 2019 May 1;98(20). |
dc.relation.references | Platteel ACM, Wevers BA, Lim J, Bakker JA, Bontkes HJ, Curvers J, et al. Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients. J Transl Autoimmun
[Internet]. 2019;2:100013. Available from: https://www.sciencedirect.com/science/article/pii/S2589909019300139 |
dc.relation.references | Selva-O’Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, GrauJunyent JM, Mammen AL. Classification and management of adult inflammatory myopathies. Lancet Neurol [Internet]. 2018 Sep 1;17(9):816–28. Available from: https://doi.org/10.1016/S1474-4422(18)30254-0 |
dc.relation.references | Joyce NC, Oskarsson B, Jin LW. Muscle Biopsy Evaluation in Neuromuscular Disorders. Phys Med Rehabil Clin N Am [Internet]. 2012;23(3):609–31. Available from: https://www.sciencedirect.com/science/article/pii/S1047965112000459 |
dc.relation.references | Staron RS, Hagerman FC, Hikida RS, Murray TF, Hostler DP, Crill MT, et al. Fiber Type Composition of the Vastus Lateralis Muscle of Young Men and Women. Journal of Histochemistry & Cytochemistry [Internet]. 2000 May 1;48(5):623–9. Available from: https://doi.org/10.1177/002215540004800506 |
dc.relation.references | Witt LJ, Curran JJ, Strek ME. The diagnosis and treatment of antisynthetase syndrome. Clin Pulm Med. 2016;23(5):218–26. |
dc.relation.references | Barsotti S, Lundberg IE. Current Treatment for Myositis. Curr Treatm Opt Rheumatol. 2018 Dec;4(4):299–315. |
dc.relation.references | Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol [Internet]. 2018 Nov 2;28(6):913–21. Available from: https://doi.org/10.1080/14397595.2018.1467257 |
dc.relation.references | Rothwell S, Cooper RG, Lamb JA, Chinoy H. Europe PMC Funders Group Strategies for Evaluating Idiopathic Inflammatory Myopathy Disease Susceptibility Genes. 2015;16(10). |
dc.relation.references | Salazar-Villa G, Rodríguez-Prada C, Bonfante-Tamara M, Restrepo-Correa R, Rodríguez-Padilla LM, Mesa-Navas MA, et al. Clinical characterisation of patients with inflammatory myopathy in 2 tertiary care hospitals in Colombia: A descriptive survey. Revista Colombiana de Reumatologia. 2022 Jan 1;29(1):9–18. |
dc.relation.references | Santos VA, Aragón CC, Posso-Osorio I, Obando MA, Barrera T, Zamorano L, et al. Caracterización epidemiológica de pacientes con miopatía inflamatoria en un hospital de cuarto nivel en Cali, Colombia. Revista Colombiana de Reumatología [Internet]. 2022;29(1):83–8. Available from: https://www.elsevier.es/es-revistarevista-colombiana-reumatologia-374-articulo-caracterizacion-epidemiologicapacientes-con-miopatia-S0121812320301638 |
dc.relation.references | Bernal-Macías S, Fernández-Ávila DG, Rincón-Riaño DN, Gutiérrez JM, Rosselli D. Prevalence of inflammatory myopathies in Colombia: Demographic analysis from the National Health Registry 2012–2018. Revista Colombiana de Reumatología [Internet]. 2023;30(2):81–6. Available from: https://www.sciencedirect.com/science/article/pii/S0121812321001262 |
dc.relation.references | Valenzuela A, Torres M, Devés JD. Performance of the 2017 EULAR/ACR criteria for idiopathic inflammatory myopathies in a cohort of patients from Latin America. Medicine (United States). 2022 Oct 28;101(43):E31015. |
dc.relation.references | Zamudio GL, Barbosa Cobos RE, Solorzano Ruiz A, Morales EL, Delgado Ochoa D. HLA class I and II alleles may influence susceptibility to adult dermatomyositis in a Mexican mestizo population. Int J Clin Rheumtol. 2018;13(2). |
dc.relation.references | Arechiga T, Villareal M, Villafranca J, Perez I, Lozoya A, Delgado D. Seventeen myositis autoantibodies: serological profile of hispanic patients with idiopathic inflammatory myopathies. In BMJ; 2018. p. 1536.3-1537. |
dc.relation.references | Nuño L, Nuño N, Joven B, Carreira P, Maldonado V, Larena C, et al. Multicenter Registry on Inflammatory Myositis From the Rheumatology Society in Madrid, Spain: Descriptive Analysis. Vol. 13, Reumatol Clin. 2017. |
dc.relation.references | Leclair V, Galindo-Feria AS, Rothwell S, Kryštůfková O, Zargar SS, Mann H, et al. Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies. EBioMedicine. 2023 Oct 1;96. |
dc.relation.references | Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EKL. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Vol. 52, Clinical Reviews in Allergy and Immunology.
Humana Press Inc.; 2017. |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |
dc.subject.decs | Miotoxicidad |
dc.subject.decs | Myotoxicity |
dc.subject.decs | Miositis |
dc.subject.decs | Myositis |
dc.subject.decs | Autoanticuerpos |
dc.subject.decs | Autoantibodies |
dc.subject.decs | Anticuerpos Fosfo-Específicos |
dc.subject.decs | Antibodies, Phospho-Specific |
dc.subject.proposal | Dermatomiositis |
dc.subject.proposal | Polimiositis |
dc.subject.proposal | Autoanticuerpos |
dc.subject.proposal | HLA |
dc.subject.proposal | Dermatomyositis |
dc.subject.proposal | Polymyositis |
dc.subject.proposal | Autoantibodies |
dc.title.translated | Prevalence and co-prevalence of immunogenetic factors in patients with idiopathic inflammatory idiopathic myopathies in a third level of complexity |
dc.type.coar | http://purl.org/coar/resource_type/c_db06 |
dc.type.coarversion | http://purl.org/coar/version/c_ab4af688f83e57aa |
dc.type.content | Text |
dc.type.redcol | http://purl.org/redcol/resource_type/TD |
oaire.accessrights | http://purl.org/coar/access_right/c_abf2 |
dcterms.audience.professionaldevelopment | Estudiantes |
dcterms.audience.professionaldevelopment | Investigadores |
dcterms.audience.professionaldevelopment | Maestros |